Today: 7 February 2026
Subscribe

Sealed Air (SEE) Soars to 52‑Week High as Clayton Dubilier & Rice Weighs Take‑Private Deal

Sealed Air (SEE) Soars to 52‑Week High as Clayton Dubilier & Rice Weighs Take‑Private Deal

Sealed Air Corporation (NYSE: SEE), maker of Bubble Wrap, jumped to a 52‑week high on November 13, 2025, as private‑equity firm Clayton Dubilier & Rice reportedly explores a take‑private deal. Here’s what’s driving SEE stock today, including fresh buyout rumors, Q3 2025 earnings, analyst targets, and key risks. Sealed Air Corporation (NYSE: SEE) is suddenly one of Wall Street’s hottest tickers. The packaging company behind Bubble Wrap and Cryovac is rallying sharply today after multiple reports that private‑equity giant Clayton, Dubilier & Rice (CD&R) is exploring a takeover that could take Sealed Air private. By late morning on Thursday, SEE
13 November 2025
····
IRS Raises 2026 401(k) and IRA Contribution Limits: New $24,500 Cap, Higher Catch‑Ups and Roth Rules Explained

IRS Raises 2026 401(k) and IRA Contribution Limits: New $24,500 Cap, Higher Catch‑Ups and Roth Rules Explained

On Thursday, November 13, 2025, the IRS released Notice 2025‑67, confirming the official contribution limits for tax‑advantaged retirement accounts in 2026. The headline change: workers will be allowed to defer up to $24,500 into 401(k)s and similar workplace plans next year—$1,000 more than in 2025—while the IRA limit increases to $7,500. IRS+1 The announcement immediately drew coverage from major outlets including MarketWatch, the Wall Street Journal, CNBC, and the Detroit Free Press, all highlighting that older savers get even more room via expanded “catch‑up” contributions and that high earners will face new Roth rules starting in 2026. linkedin.com+3MarketWatch+3The Wall Street
13 November 2025
·
Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics (NASDAQ: OTLK) shares jumped today after the U.S. FDA accepted the company’s resubmitted Biologics License Application (BLA) for ONS‑5010/LYTENAVA, its bevacizumab-based eye drug for wet AMD, and set a PDUFA review date of December 31, 2025. Here’s what investors need to know. What Outlook Therapeutics announced today This morning, Outlook Therapeutics, Inc. (NASDAQ: OTLK) announced that the U.S. Food and Drug Administration has accepted the company’s resubmitted Biologics License Application for ONS‑5010 (bevacizumab‑vikg)/LYTENAVA, its investigational ophthalmic formulation of bevacizumab for the treatment of wet age‑related macular degeneration (wet AMD). GlobeNewswire+2Outlook Therapeutics+2 According to the company’s press release and
13 November 2025
····
Northland Power (TSX:NPI) Stock Plunges as Q3 2025 Revenue Beat is Overshadowed by 40% Dividend Cut and Hai Long Delay

Northland Power (TSX:NPI) Stock Plunges as Q3 2025 Revenue Beat is Overshadowed by 40% Dividend Cut and Hai Long Delay

Northland Power Inc. (TSX: NPI, NPI.TO) is under heavy pressure today after reporting third‑quarter 2025 results, cutting its dividend by 40% and warning that delays at its flagship Hai Long offshore wind project could hit 2026 revenues. The stock is trading around C$19 today, down more than 20% from Wednesday’s close near C$25, according to intraday quote data. StockInvest+1 Key Takeaways for Investors Q3 2025: Revenue Beat, Heavy Impairment Northland Power’s Q3 2025 numbers paint a mixed picture: strong operations and cash flow on one side, a sizeable accounting hit on the other. According to the company’s Q3 press release:
13 November 2025
·····
Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Vancouver / Jerusalem – November 13, 2025 – Shares of Clearmind Medicine Inc. (NASDAQ: CMND), a clinical‑stage psychedelic and neuroplastogen biotech company, jumped sharply on Thursday after the firm announced final approval to expand its FDA‑regulated Phase 1/2a clinical trial for Alcohol Use Disorder (AUD) to Hadassah Medical Center in Jerusalem. GlobeNewswire+1 At the same time, Clearmind filed a new Form 6‑K detailing a registered direct offering of shares and pre‑funded warrants, adding fresh capital but also raising dilution questions for investors. Stock Titan Below is a full breakdown of today’s key developments and what they mean for CMND stock.
13 November 2025
····
Manulife (MFC.TO) Hits Record High on Q3 Beat, India Mahindra JV and $350M Longevity Push

Manulife (MFC.TO) Hits Record High on Q3 Beat, India Mahindra JV and $350M Longevity Push

Manulife Financial Corporation (TSX: MFC, NYSE: MFC) has packed a full strategic reset, fresh Asian expansion, and a record quarter of earnings momentum into just a couple of days — and the market is cheering. Shares of Manulife jumped as much as 3.3% today to an all‑time high of C$49.82 in Toronto after the Canadian insurer beat Q3 estimates, unveiled a refreshed growth strategy, and confirmed a 50:50 life‑insurance joint venture in India with Mahindra & Mahindra. Reuters+1 Below is a full rundown of everything investors need to know about Manulife’s news flow around 13 November 2025 — from earnings
13 November 2025
···
Alien Probe or Cosmic Relic? Interstellar Comet 3I/ATLAS Baffles Scientists (updated 27.10.2025)

3I/ATLAS Today (Nov. 13, 2025): Interstellar comet’s tail keeps growing, ‘radio signal’ confirmed natural, and a different ATLAS comet fragments

Published Thursday, November 13, 2025 Fresh observations today keep 3I/ATLAS—the third confirmed interstellar object—firmly in the “strange but natural comet” camp. Meanwhile, a different ATLAS‑discovered comet in our solar system, C/2025 K1 (ATLAS), is visibly fragmenting. Here’s what changed today, what didn’t, and how to tell these two “ATLAS comets” apart. ScienceAlert+2NASA Science+2 What’s new today (Nov. 13) The science behind the week’s biggest talking points The “radio signal” explained.MeerKAT detected OH absorption at the familiar radio frequencies used to trace water loss in comets. That’s direct evidence that 3I/ATLAS is venting water as it warms—exactly what a coma should
13 November 2025
···
Nebius (NBIS) Stock Slides After Q3 2025 Earnings: $3B Meta AI Deal, Microsoft Pact and CoreWeave Rivalry, Explained

Nebius (NBIS) Stock Slides After Q3 2025 Earnings: $3B Meta AI Deal, Microsoft Pact and CoreWeave Rivalry, Explained

Nebius Group (NASDAQ: NBIS) has just delivered one of the most dramatic weeks in the AI‑infrastructure trade: Today, November 13, Nebius shares are trading back in the high‑$80s, down around 6% intraday and more than 30% off recent highs near $140, even after a year in which the stock has more than quadrupled. StockAnalysis+2MarketBeat+2 At the same time, rival AI “neocloud” player CoreWeave is also under pressure after slashing capital‑expenditure guidance and trimming its 2025 outlook, forcing investors to choose which high‑growth, high‑spend AI infrastructure story they trust more. Investors.com+2Business Insider+2 Here’s what’s really driving Nebius stock today, why some
13 November 2025
····
VisionSys AI (VSA) Crashes Nearly 78% After $12 Million Direct Offering as Shareholders Head Into High‑Stakes Vote

VisionSys AI (VSA) Crashes Nearly 78% After $12 Million Direct Offering as Shareholders Head Into High‑Stakes Vote

VisionSys AI Inc. (NASDAQ: VSA) has become one of Wall Street’s most talked‑about micro‑caps after its shares collapsed nearly 78% in a single session, wiping out most of its recent gains and putting fresh scrutiny on the company’s aggressive capital‑raising and crypto‑treasury ambitions.StockAnalysis+1 As of early Thursday trading, the stock is hovering around $0.28 with heavy volume, slightly below Wednesday’s close at $0.29, keeping VisionSys firmly among the market’s biggest losers heading into a crucial extraordinary general meeting (EGM) scheduled for today in New York.Fast Edgar Archive Stock in Freefall: From Micro‑Cap Momentum to Nasdaq’s Worst Performer VisionSys AI’s collapse
13 November 2025
···
Rigetti Computing (RGTI) News Today – 13 November 2025: CEO’s $11 Million Trade, Short-Seller Pressure and Fresh Institutional Buying

Rigetti Computing (RGTI) News Today – 13 November 2025: CEO’s $11 Million Trade, Short-Seller Pressure and Fresh Institutional Buying

Rigetti Computing, Inc. (NASDAQ: RGTI) — one of the market’s most volatile quantum computing stocks — is back in the spotlight today, 13 November 2025, as new headlines hit around insider activity, short-seller scrutiny, fresh institutional buying, and the fallout from last week’s Q3 earnings. Below is a full rundown of all the key Rigetti news circulating today, plus the context from recent earnings and the company’s quantum roadmap. Key Takeaways RGTI Stock Today: Volatility After a Massive Quantum Rally Rigetti has become one of 2025’s wildest trades. According to StockAnalysis data, RGTI closed at $26.40 on 13 November 2025,
13 November 2025
···
DLocal (DLO) Stock Tumbles After Record Q3 2025 Earnings and New WhatsApp Remittance Push

DLocal (DLO) Stock Tumbles After Record Q3 2025 Earnings and New WhatsApp Remittance Push

Uruguay-based fintech DLocal Limited (NASDAQ: DLO) is having a volatile week. After closing 2.34% higher at $14.86 on Wednesday following record third‑quarter 2025 results, the stock is down around 9% on Thursday, November 13, trading near $13.5 in late-morning New York, as investors focus on margin pressure and softer economics in key markets. Parameter+1 At the same time, DLocal has announced a high‑profile stablecoin-funded WhatsApp remittance partnership with Félix, underlining its push deeper into cross-border payments and crypto rails across Latin America. FF News | Fintech Finance DLO stock: From earnings pop to post-earnings hangover Despite today’s drop, DLocal shares
13 November 2025
···
TNL Mediagene (TNMG) Stock Explodes on Coupang Deal: What Today’s Partnership Means for Taiwan’s Content Commerce Boom – 13 November 2025

TNL Mediagene (TNMG) Stock Explodes on Coupang Deal: What Today’s Partnership Means for Taiwan’s Content Commerce Boom – 13 November 2025

TNL Mediagene (NASDAQ: TNMG) is back in the spotlight today after unveiling a strategic partnership with U.S. Fortune 150 technology and e‑commerce company Coupang, Inc. (NYSE: CPNG), focused on the fast‑growing Taiwan market. PR Newswire The Tokyo‑headquartered digital media and data group says the alliance is designed to supercharge its Content Commerce and Retail Media Network ecosystem across a suite of premium media brands, from The News Lens to Business Insider Taiwan and iCook. PR Newswire Investors have reacted with enthusiasm. As of mid‑morning on November 13, 2025, TNMG shares were trading around $0.44, up roughly 46% on the day,
13 November 2025
···
1 … 2,185 2,186 2,187 2,188 2,189 … 2,707

Stock Market Today

REA share price tumbles after results as listings outlook bites; buyback and dividend dates loom

7 February 2026
Sydney, Feb 7, 2026, 16:49 AEDT — Market closed REA Group shares closed down 7.8% on Friday at A$168.10 after the online property advertising group laid out a softer listings outlook. The stock opened sharply lower at A$150.01 and traded in a A$150.01–A$172.80 range. (Investing.com Australia) The drop landed in a broad risk-off session, with the ASX 200 ending about 2% lower. “Panic is spreading,” said Michael McCarthy at MooMoo Australia, as investors headed for the exits across markets. (ABC News) REA said revenue from core operations — which strips out one-off items — rose 5% to A$916 million in
CSL share price in focus after ASX sell-off: what investors watch before Feb 11 results

CSL share price in focus after ASX sell-off: what investors watch before Feb 11 results

7 February 2026
CSL Limited shares closed down 0.4% at A$180.50 Friday as the S&P/ASX 200 dropped 2.03% to 8,708.80. CSL will report half-year results and announce its interim dividend on Feb. 11, with the stock set to trade ex-dividend March 10. A filing showed 59,992 CSL conditional rights lapsed this week. The company’s market value stands near A$87 billion, down about a third in the past year.
Go toTop